Next Article in Journal
Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study
Previous Article in Journal
Cost Analysis of Laparoscopic Low Anterior Resection vs. Transanal Endoscopic Microsurgery for Rectal Neoplasms
Review

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

1
College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
2
Saskatoon Cancer Center, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 1803-1822; https://doi.org/10.3390/curroncol28030168
Received: 30 March 2021 / Revised: 21 April 2021 / Accepted: 6 May 2021 / Published: 11 May 2021
Background: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the past decades, the emergence of novel targeted therapy in combination with endocrine therapy has shown improvement in outcomes of HR + BC. This paper reviews available data of targeted therapy and the results of pivotal clinical trials in the management of HR + BC. Methods: A literature search in PubMed and Google Scholar was performed using keywords related to HR + BC and targeted therapy. Major relevant studies that were presented in international cancer research conferences were also included. Results: Endocrine therapy with tamoxifen and aromatase inhibitors are backbone treatments for women with early-stage HR + BC leading to a significant reduction in mortality. They can also be used for primary prevention in women with a high risk of breast cancer. Preliminary data has shown the efficacy of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor, abemaciclib, in high-risk disease in combination with aromatase inhibitors. For most women with advanced HR + BC, endocrine therapy is the primary treatment. Recent evidence has shown that the use of CKD 4/6 inhibitors, mTOR inhibitors, and PI3K inhibitors in combination with endocrine therapy has been associated with better outcomes and delays initiation of chemotherapy. Several novel agents are under study for HR + BC. Discussion: Targeted treatment options for HR + BC have evolved. The future of overcoming resistance to targeted therapy, novel compounds, and predictive markers are key to improving HR + BC outcomes. View Full-Text
Keywords: breast cancer; hormone receptor-positive breast cancer; estrogen receptor-positive-breast cancer; systemic therapy; targeted therapy; antiestrogen therapy; selective estrogen receptor modulator; selective estrogen receptor degraders; cyclin-dependent kinases 4 and 6 inhibitors; aromatase inhibitors breast cancer; hormone receptor-positive breast cancer; estrogen receptor-positive-breast cancer; systemic therapy; targeted therapy; antiestrogen therapy; selective estrogen receptor modulator; selective estrogen receptor degraders; cyclin-dependent kinases 4 and 6 inhibitors; aromatase inhibitors
MDPI and ACS Style

Andrahennadi, S.; Sami, A.; Manna, M.; Pauls, M.; Ahmed, S. Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. Curr. Oncol. 2021, 28, 1803-1822. https://doi.org/10.3390/curroncol28030168

AMA Style

Andrahennadi S, Sami A, Manna M, Pauls M, Ahmed S. Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. Current Oncology. 2021; 28(3):1803-1822. https://doi.org/10.3390/curroncol28030168

Chicago/Turabian Style

Andrahennadi, Samitha, Amer Sami, Mita Manna, Mehrnoosh Pauls, and Shahid Ahmed. 2021. "Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer" Current Oncology 28, no. 3: 1803-1822. https://doi.org/10.3390/curroncol28030168

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop